Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

A video-based, flipped classroom, simulation curriculum for dermatologic surgery: A prospective, multi-institution study.

Liu KJ, Tkachenko E, Waldman A, Boskovski MT, Hartman RI, Levin AA, Nguyen BM, Ruiz ES, Sharon VR, Sowerby L, Tiger J, Yang FC, Mostaghimi A.

J Am Acad Dermatol. 2019 Apr 3. pii: S0190-9622(19)30523-7. doi: 10.1016/j.jaad.2019.03.078. [Epub ahead of print]

PMID:
30953701
2.

Treating Disease at the RNA Level with Oligonucleotides.

Levin AA.

N Engl J Med. 2019 Jan 3;380(1):57-70. doi: 10.1056/NEJMra1705346. Review. No abstract available.

PMID:
30601736
3.

Knowledge of melanoma and nonmelanoma skin cancer among general dermatology patients.

Levin AA, Nguyen BM.

J Am Acad Dermatol. 2018 Nov;79(5):964-966. doi: 10.1016/j.jaad.2018.04.054. Epub 2018 May 10. No abstract available.

PMID:
29753063
4.

Targeting Therapeutic Oligonucleotides.

Levin AA.

N Engl J Med. 2017 Jan 5;376(1):86-88. doi: 10.1056/NEJMcibr1613559. No abstract available.

PMID:
28052219
5.

Synthesis and Three-Dimensional Magnetic Field Mapping of Co2FeGa Heusler Nanowires at 5 nm Resolution.

Simon P, Wolf D, Wang C, Levin AA, Lubk A, Sturm S, Lichte H, Fecher GH, Felser C.

Nano Lett. 2016 Jan 13;16(1):114-20. doi: 10.1021/acs.nanolett.5b03102. Epub 2015 Dec 23.

PMID:
26674206
6.

Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial.

van Poelgeest EP, Hodges MR, Moerland M, Tessier Y, Levin AA, Persson R, Lindholm MW, Dumong Erichsen K, Ørum H, Cohen AF, Burggraaf J.

Br J Clin Pharmacol. 2015 Dec;80(6):1350-61. doi: 10.1111/bcp.12738. Epub 2015 Oct 24.

7.

The International Dermatology Outcome Measures Group: formation of patient-centered outcome measures in dermatology.

Gottlieb AB, Levin AA, Armstrong AW, Abernethy A, Duffin KC, Bhushan R, Garg A, Merola JF, Maccarone M, Christensen R.

J Am Acad Dermatol. 2015 Feb;72(2):345-8. doi: 10.1016/j.jaad.2014.11.002. Epub 2014 Dec 6.

PMID:
25486914
8.

Basal cell carcinoma of the perineum.

Levin AA, Dabade T, Dandekar M, Rogers G, Rosmarin D.

Dermatol Online J. 2014 Aug 17;20(8). pii: 13030/qt4w9384n2.

PMID:
25148280
9.

A randomized, prospective, sham-controlled study of localized narrow-band UVB phototherapy in the treatment of plaque psoriasis.

Levin AA, Aleissa S, Dumont N, Martinez F, Donovan C, Au SC, Hasanain A, Gottlieb AB.

J Drugs Dermatol. 2014 Aug;13(8):922-6.

PMID:
25116969
10.

Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum.

Henry SP, Jagels MA, Hugli TE, Manalili S, Geary RS, Giclas PC, Levin AA.

Nucleic Acid Ther. 2014 Oct;24(5):326-35. doi: 10.1089/nat.2014.0491. Epub 2014 Aug 5.

PMID:
25093529
11.
12.

Changing the research landscape: the New York City Clinical Data Research Network.

Kaushal R, Hripcsak G, Ascheim DD, Bloom T, Campion TR Jr, Caplan AL, Currie BP, Check T, Deland EL, Gourevitch MN, Hart R, Horowitz CR, Kastenbaum I, Levin AA, Low AF, Meissner P, Mirhaji P, Pincus HA, Scaglione C, Shelley D, Tobin JN; NYC-CDRN.

J Am Med Inform Assoc. 2014 Jul-Aug;21(4):587-90. doi: 10.1136/amiajnl-2014-002764. Epub 2014 May 12.

13.

Treatment of idiopathic intracranial hypertension with gastric bypass surgery.

Levin AA, Hess D, Hohler AD.

Int J Neurosci. 2015 Jan;125(1):78-80. doi: 10.3109/00207454.2014.898144. Epub 2014 Mar 25.

PMID:
24579748
14.

Specific targeting of interleukin-23p19 as effective treatment for psoriasis.

Levin AA, Gottlieb AB.

J Am Acad Dermatol. 2014 Mar;70(3):555-61. doi: 10.1016/j.jaad.2013.10.043. Epub 2013 Dec 24. Review.

PMID:
24373779
15.

Continuous versus intermittent therapy for moderate-to-severe psoriasis.

Ramirez-Fort MK, Levin AA, Au SC, Gottlieb AB.

Clin Exp Rheumatol. 2013 Jul-Aug;31(4 Suppl 78):S63-70. Epub 2013 Oct 4. Review.

PMID:
24129141
16.

Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9.

van Poelgeest EP, Swart RM, Betjes MG, Moerland M, Weening JJ, Tessier Y, Hodges MR, Levin AA, Burggraaf J.

Am J Kidney Dis. 2013 Oct;62(4):796-800. doi: 10.1053/j.ajkd.2013.02.359. Epub 2013 Apr 3.

PMID:
23561896
17.

Treatment of HCV infection by targeting microRNA.

Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR.

N Engl J Med. 2013 May 2;368(18):1685-94. doi: 10.1056/NEJMoa1209026. Epub 2013 Mar 27.

18.

Assessing unintended hybridization-induced biological effects of oligonucleotides.

Lindow M, Vornlocher HP, Riley D, Kornbrust DJ, Burchard J, Whiteley LO, Kamens J, Thompson JD, Nochur S, Younis H, Bartz S, Parry J, Ferrari N, Henry SP, Levin AA.

Nat Biotechnol. 2012 Oct;30(10):920-3. doi: 10.1038/nbt.2376. No abstract available.

PMID:
23051805
19.

Developing microRNA therapeutics: approaching the unique complexities.

Jackson AL, Levin AA.

Nucleic Acid Ther. 2012 Aug;22(4):213-25. doi: 10.1089/nat.2012.0356. Review.

PMID:
22913594
20.

The Oligonucleotide Safety Working Group (OSWG).

Schubert D, Levin AA, Kornbrust D, Berman CL, Cavagnaro J, Henry S, Seguin R, Ferrari N, Shrewsbury SB.

Nucleic Acid Ther. 2012 Aug;22(4):211-2. doi: 10.1089/nat.2012.0383. No abstract available.

PMID:
22913593
21.

Renal uptake and tolerability of a 2'-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey.

Henry SP, Johnson M, Zanardi TA, Fey R, Auyeung D, Lappin PB, Levin AA.

Toxicology. 2012 Nov 15;301(1-3):13-20. doi: 10.1016/j.tox.2012.06.005. Epub 2012 Jun 16.

PMID:
22709826
22.

Developing microRNA therapeutics.

van Rooij E, Purcell AL, Levin AA.

Circ Res. 2012 Feb 3;110(3):496-507. doi: 10.1161/CIRCRESAHA.111.247916. Review.

PMID:
22302756
23.

Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through.

Hoffman EP, Bronson A, Levin AA, Takeda S, Yokota T, Baudy AR, Connor EM.

Am J Pathol. 2011 Jul;179(1):12-22. doi: 10.1016/j.ajpath.2011.03.050. Epub 2011 May 23. Review.

24.

Switching Ti valence in SrTiO3 by a dc electric field.

Leisegang T, Stöcker H, Levin AA, Weissbach T, Zschornak M, Gutmann E, Rickers K, Gemming S, Meyer DC.

Phys Rev Lett. 2009 Feb 27;102(8):087601. Epub 2009 Feb 23.

PMID:
19257786
25.

Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides improves insulin sensitivity and increases adiponectin concentrations in monkeys.

Swarbrick MM, Havel PJ, Levin AA, Bremer AA, Stanhope KL, Butler M, Booten SL, Graham JL, McKay RA, Murray SF, Watts LM, Monia BP, Bhanot S.

Endocrinology. 2009 Apr;150(4):1670-9. doi: 10.1210/en.2008-0885. Epub 2009 Jan 22.

26.

Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.

Yu RZ, Lemonidis KM, Graham MJ, Matson JE, Crooke RM, Tribble DL, Wedel MK, Levin AA, Geary RS.

Biochem Pharmacol. 2009 Mar 1;77(5):910-9. doi: 10.1016/j.bcp.2008.11.005. Epub 2008 Nov 14.

PMID:
19056355
27.

Assessment of the effects of ISIS 2302, an anti-sense inhibitor of human ICAM-1, on cellular and humoral immunity in mice.

Henry SP, Levin AA, White K, Mennear JH.

J Immunotoxicol. 2006 Dec 1;3(4):199-211. doi: 10.1080/15476910601046538.

PMID:
18958701
28.

CpG and Non-CpG oligodeoxynucleotides induce differential proinflammatory gene expression profiles in liver and peripheral blood leukocytes in mice.

Younis HS, Vickers T, Levin AA, Henry SP.

J Immunotoxicol. 2006 Jul 1;3(2):57-68. doi: 10.1080/15476910600718236.

PMID:
18958686
29.

Chronic diverticulitis: clinical, radiographic, and pathologic findings.

Sheiman L, Levine MS, Levin AA, Hogan J, Rubesin SE, Furth EE, Laufer I.

AJR Am J Roentgenol. 2008 Aug;191(2):522-8. doi: 10.2214/AJR.07.3597.

PMID:
18647926
30.

An 8-year review of barium studies in the diagnosis of gastroparesis.

Levin AA, Levine MS, Rubesin SE, Laufer I.

Clin Radiol. 2008 Apr;63(4):407-14. doi: 10.1016/j.crad.2007.10.007. Epub 2007 Dec 20.

PMID:
18325361
31.

Materials: carbon nanotubes in an ancient Damascus sabre.

Reibold M, Paufler P, Levin AA, Kochmann W, Pätzke N, Meyer DC.

Nature. 2006 Nov 16;444(7117):286.

PMID:
17108950
32.

The FDA and drug safety: a proposal for sweeping changes.

Furberg CD, Levin AA, Gross PA, Shapiro RS, Strom BL.

Arch Intern Med. 2006 Oct 9;166(18):1938-42.

PMID:
17030825
33.

Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302).

Watanabe TA, Geary RS, Levin AA.

Oligonucleotides. 2006 Summer;16(2):169-80.

PMID:
16764540
34.

Maternal and fetal distribution of a phosphorothioate oligonucleotide in rats after intravenous infusion.

Soucy NV, Riley JP, Templin MV, Geary R, de Peyster A, Levin AA.

Birth Defects Res B Dev Reprod Toxicol. 2006 Feb;77(1):22-8.

PMID:
16496297
35.

Patient safety: rejecting the status quo.

Levin AA.

N C Med J. 2005 Mar-Apr;66(2):91-5. No abstract available.

PMID:
15952457
36.

Distribution and excretion of a phosphorothioate oligonucleotide in rats with experimentally induced renal injury.

Masarjian L, de Peyster A, Levin AA, Monteith DK.

Oligonucleotides. 2004 Winter;14(4):299-310.

PMID:
15665597
37.

Effects of an antisense oligonucleotide inhibitor of human ICAM-1 on fetal development in rabbits.

Henry SP, Denny KH, Templin MV, Yu RZ, Levin AA.

Birth Defects Res B Dev Reprod Toxicol. 2004 Dec;71(6):368-73.

PMID:
15617022
38.

Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice.

Henry SP, Denny KH, Templin MV, Yu RZ, Levin AA.

Birth Defects Res B Dev Reprod Toxicol. 2004 Dec;71(6):359-67.

PMID:
15617021
39.
40.

Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate.

Raoof AA, Chiu P, Ramtoola Z, Cumming IK, Teng C, Weinbach SP, Hardee GE, Levin AA, Geary RS.

J Pharm Sci. 2004 Jun;93(6):1431-9.

PMID:
15124202
41.

Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys.

Yu RZ, Geary RS, Monteith DK, Matson J, Truong L, Fitchett J, Levin AA.

J Pharm Sci. 2004 Jan;93(1):48-59.

PMID:
14648635
42.

Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.

Geary RS, Yu RZ, Watanabe T, Henry SP, Hardee GE, Chappell A, Matson J, Sasmor H, Cummins L, Levin AA.

Drug Metab Dispos. 2003 Nov;31(11):1419-28.

PMID:
14570775
43.

Ocular findings in lissencephaly.

Nabi NU, Mezer E, Blaser SI, Levin AA, Buncic JR.

J AAPOS. 2003 Jun;7(3):178-84.

PMID:
12825057
44.
45.

More on science and politics.

Bass GD, Blumenthal PD, Corfman P, Darney PD, Gonsalves G, Levin AA, Trussell J, Shields WC.

Science. 2003 Feb 28;299(5611):1313. No abstract available.

PMID:
12610277
46.

Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide.

Henry SP, Beattie G, Yeh G, Chappel A, Giclas P, Mortari A, Jagels MA, Kornbrust DJ, Levin AA.

Int Immunopharmacol. 2002 Nov;2(12):1657-66.

PMID:
12469940
47.

The restorative effect of naps on perceptual deterioration.

Mednick SC, Nakayama K, Cantero JL, Atienza M, Levin AA, Pathak N, Stickgold R.

Nat Neurosci. 2002 Jul;5(7):677-81.

PMID:
12032542
48.

Assessment of the genotoxic potential of ISIS 2302: a phosphorothioate oligodeoxynucleotide.

Henry SP, Monteith DK, Matson JE, Mathison BH, Loveday KS, Winegar RA, Matson JE, Lee PS, Riccio ES, Bakke JP, Levin AA.

Mutagenesis. 2002 May;17(3):201-9.

PMID:
11971990
49.
50.

Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?

Henry SP, Geary RS, Yu R, Levin AA.

Curr Opin Investig Drugs. 2001 Oct;2(10):1444-9.

PMID:
11890363

Supplemental Content

Loading ...
Support Center